NASPGHAN Position Paper Outlines Therapeutic Drug Monitoring Targets for Pediatric IBD - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

NASPGHAN Position Paper Outlines Therapeutic Drug Monitoring Targets for Pediatric IBD

  • By

  • November 11, 2026

  • 5 min

Share

Clinical Scorecard: NASPGHAN Position Paper Outlines Therapeutic Drug Monitoring Targets for Pediatric IBD

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: NASPGHAN Position Paper Outlines Therapeutic Drug Monitoring Targets for Pediatric IBD
Key MechanismsTherapeutic drug monitoring measures biologic blood levels to guide dosing; anti-TNF monitoring also tracks antibodies against the drug.
Target PopulationChildren with Crohn’s disease or ulcerative colitis receiving biologic therapy; the source notes that children with perianal fistulas may need higher drug levels and those diagnosed before age 6 may clear infliximab faster.
Care SettingCare setting described in the source article.

Key Highlights

  • The 2025 NASPGHAN position paper recommends infliximab trough levels above 18 micrograms per milliliter at week 6 and above 7 micrograms per milliliter at week 14.
  • The paper recommends proactive infliximab monitoring every 6 to 12 months during maintenance.
  • Children with perianal fistulas may need higher drug levels; children diagnosed before age 6 may clear infliximab faster and need more intensive dosing and close monitoring.
  • Proactive monitoring checks drug levels before problems appear; reactive monitoring checks levels after a problem develops.
  • For newer biologics, monitoring focuses on drug levels, with less concern about antibody formation than with anti-TNF therapy.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • A trough level is the lowest drug level, measured just before the next dose.
      • The position paper recommends proactive infliximab monitoring every 6 to 12 months during maintenance.

      Risks

      • Reactive monitoring may occur too late to make changes that keep a child on the current therapy; a switch may be needed.
      • Potential signs of active disease include diarrhea, blood in stool, weight loss, abdominal pain, growth failure, joint pain, skin rashes, eye or mouth involvement, and abnormal liver tests.

      Patient & Prescribing Data

      Children with Crohn’s disease or ulcerative colitis treated with biologics; the source notes fewer medication options for children than for adults with IBD.

      Infliximab trough targets are above 18 micrograms per milliliter at week 6 and above 7 micrograms per milliliter at week 14, followed by proactive monitoring every 6 to 12 months during maintenance. Some children may need higher levels, more intensive dosing, or closer monitoring.

      Clinical Best Practices

      • Discuss concerns about active disease in a child receiving a biologic with a pediatric IBD specialist.
      • Assess for symptoms outside the gut as well as intestinal symptoms.

      Related Resources & Content

      Original Source(s)

      Related Content